14-15-dihydroxyeicosatrienoic-acid has been researched along with Coronary-Disease* in 2 studies
2 other study(ies) available for 14-15-dihydroxyeicosatrienoic-acid and Coronary-Disease
Article | Year |
---|---|
The role of 14,15-dihydroxyeicosatrienoic acid levels in inflammation and its relationship to lipoproteins.
14,15-Epoxyeicosatrienoic acids (14,15-EETs) generated from arachidonic acid by cytochrome P450 epoxygenases have beneficial effects in certain cardiovascular diseases, and increased 14,15-EET levels protect the cardiovascular system. 14,15-EETs are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the corresponding 14,15-dihydroxyeicosatrienoic acids (14,15-DHETs), which are generally less biologically active but more stable metabolite. A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary heart disease (CHD), and the major CYP2J2 product is 14,15-EETs. 14,15-DHETs can be considered a relevant marker of CYP2J2 activity. Therefore, the aim of the present study was to evaluate the plasma 14,15-DHET levels to reflect the 14,15-EET levels in an indirectly way in patients with CHD, and to highlight the growing body of evidence that 14,15-EETs also play a role in anti-inflammatory and lipid-regulating effects in patients with CHD. This was achieved by investigating the relationship between 14,15-DHETs and high-sensitivity C-reactive protein (hs-CRP) and blood lipoproteins.. Samples of peripheral venous blood were drawn from 60 patients with CHD and 60 healthy controls. A 14,15-DHET enzyme-linked immunosorbent assay kit (14,15-DHET ELISA kit) was used to measure the plasma 14,15-DHET levels. Hs-CRP, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein-cholesterol levels were measured.. 14,15-DHET levels (2.53 ± 1.60 ng/mL) were significantly higher in patients with CHD as compared with those of the healthy controls (1.65 ± 1.54 ng/mL, P < 0.05). There was a significant positive correlation between 14,15-DHETs and hs-CRP levels (R = 0.286, P = 0.027). However, there was no significant correlation between 14,15-DHETs and blood lipoproteins (all, P > 0.05).. Increased plasma 14,15-DHET levels reflect the decreased of 14,15-EET levels in an indirectly way. Indicated that decreased plasma 14,15-EET levels might be involved in the inflammatory reaction process in atherosclerosis. Topics: 8,11,14-Eicosatrienoic Acid; Aged; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Female; Humans; Inflammation; Male; Middle Aged; Statistics, Nonparametric; Triglycerides | 2013 |
Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.
Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs). The EETs are potent endogenous vasodilators and inhibitors of vascular inflammation. However, it is not known whether genetic polymorphisms of CYP2J2 are associated with increased cardiovascular risks.. All 9 exons of the CYP2J2 gene and its proximal promoter were sequenced in 132 patients to identify potential variants. Functional consequence of a single nucleotide polymorphism (SNP) in the promoter of CYP2J2 was further evaluated by use of transcription factor-binding and reporter assays. A total of 17 polymorphisms were identified. One of the most relevant polymorphisms in terms of frequency and functional importance is located at -50 (G-50T) in the proximal promoter of CYP2J2. Screening of 289 patients with coronary artery disease and 255 control subjects revealed 77 individuals with the G-50T SNP (17.3% of coronary artery disease patients, 10.6% of control subjects; P=0.026). The association of the G-50T polymorphism remained significant after adjustment for age, gender, and conventional cardiovascular risk factors (OR, 2.23; 95% CI, 1.04 to 4.79). The G-50T mutation resulted in the loss of binding of the Sp1 transcription factor to the CYP2J2 promoter and resulted in a 48.1+/-2.4% decrease in CYP2J2 promoter activity (P<0.01). Plasma concentrations of stable EET metabolites were significantly lower in individuals with the G-50T SNP.. A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary artery disease. Topics: 3' Untranslated Regions; 8,11,14-Eicosatrienoic Acid; Aged; Amino Acid Substitution; Arachidonic Acid; Base Sequence; Binding Sites; Coronary Disease; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; DNA Mutational Analysis; Eicosanoids; Exons; Female; Genetic Testing; Genotype; Germany; Humans; Hydroxyeicosatetraenoic Acids; Introns; Male; Middle Aged; Molecular Sequence Data; Oxygenases; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk; Sequence Analysis, DNA; Sp1 Transcription Factor | 2004 |